Canada Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

Canada Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

The Canada Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $88 Mn in 2022 and is projected to reach US $138 Mn in 2030, exhibiting a CAGR of 5.8% during the forecast period.

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder caused by mutations in the genes PKD1 and PKD2, resulting in fluid-filled cysts developing in the kidneys. These cysts expand and multiply over time, causing the kidneys to enlarge and eventually fail. ADPKD is inherited in an autosomal dominant form, which means that only one copy of the mutated gene from a parent is required for the disease to develop. Symptoms include discomfort, fatigue, urinary tract infections, and others. There is currently no cure for ADPKD; however, treatment focuses on symptom management and decreasing disease progression. The mainstay of treatment is Tolvaptan (Jinarc) developed by Otsuka Pharmaceuticals, which acts by inhibiting vasopressin, a hormone that promotes cyst growth, and has been observed to reduce cyst growth. Other therapeutic options include pain management and lifestyle modifications.

Estimates suggest that the incidence of ADPKD is around 2.7/10,000 individuals in Canada. Recently, it is reported that more than 30,000 Canadians are living with ADPKD. The market is therefore driven by major factors like increased incidence in ADPKD cases, an exponentially increasing geriatric population, improved survival rates, and the emergence of novel therapeutics in the industry. However, conditions such as high costs of treatment, several regulatory challenges in Canada, and others hinder the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in the incidence of ADPKD: Around 30,000 Canadians are currently living with ADPKD. According to PKD Canada, the approximate incidence of ADPKD in Canada is 2.7/10,000 individuals, with around 5–11% of patients diagnosed requiring dialysis. The estimates are expected to increase, which will drive market growth in the forecasted period.

Aging population: There is a higher proportion of geriatric population in Canada. With the aging Canadian population, the likelihood of developing chronic kidney conditions such as ADPKD rises. This demographic change inherently elevates the demand for ADPKD therapeutics and is expected to propel the market for growth.

Novel Therapeutics: The pipeline for ADPKD therapeutics is filled with potential drugs such as tolvaptans and vasopressin V2 receptor antagonists, including gene therapy, gene editing, and targeted small molecules. These prospective management advances could greatly increase market value.

Increased awareness: The Canadian market for ADPKD treatments is seeing growth due to the proactive efforts of both governments, such as PKD Canada, and global market developments. They advocate the need for research funding, enhanced healthcare accessibility, and public education. This propels market growth through encouraging early detection, prompt treatment commencement, and comprehensive disease management initiatives.

Market Restraints

High costs of treatment: Treatments for ADPKD, such as Tolvaptan, can be costly, causing a considerable financial burden on both patients and the healthcare system. This can restrict treatment access, especially for those with inadequate insurance coverage or limited financial means, distorting the growth of the market

Limited treatment options: Despite the emergence of new therapies, there's currently no cure for ADPKD, and existing treatments solely address symptoms. The absence of definitive solutions to manage disease advancement might deter certain patients from pursuing treatment and result in non-compliance.

Regulatory challenges: Introducing novel ADPKD therapies to the market can encounter prolonged and complicated approval procedures with Canadian regulatory agencies. This might impede patient access to potentially transformative treatments and hinder market growth.

Healthcare Policies and Regulatory Landscape

The Canada Health Act (CHA) outlines the key objectives of Canadian health care policy and regulates the country's publicly funded healthcare system. The policy aims "to protect, promote, and restore the physical and mental well-being of residents of Canada and to facilitate reasonable access to health services without direct charges at the point of service for such services."

The CHA set down standards that the territories and provinces must meet in order to be eligible for federal financing, both for extended health care services and covered health services.

Obtaining a medical license in Canada involves a province- and territory-specific process mandated by Health Canada (HC), typically necessitating the completion of a medical degree, residency training, and successful passage of licensing examinations.

Competitive Landscape

Key Players

• Pfizer Inc.
• Johnson and Johnson
• Mylan N.V
• Teva Pharmaceutical
• Sanofi
• GSK plc
• AbbVie Inc
• Novartis AG
• Eli Lily
• F. Hoffman-La Roche Ltd